Key Takeaways
- Can-Fite BioPharma received a patent from Brazil’s patent office for its A3 adenosine receptor agonists to treat sexual dysfunction on December 26, 2025.
- The company’s shares surged 47% in premarket trading following the patent announcement.
- This patent enhances Can-Fite’s intellectual property portfolio in Latin America’s largest pharmaceutical market and bolsters its development across multiple therapeutic fields.
Can-Fite BioPharma Ltd. (NYSE American: CANF) saw a significant stock jump on December 26, 2025, after Brazil’s Industrial Property National Institute (INPI) granted a patent for its A3 adenosine receptor agonists targeting sexual dysfunction. This patent solidifies Can-Fite’s intellectual property rights in Brazil, the largest pharmaceutical market in Latin America. The patent acknowledges the therapeutic potential of Can-Fite’s drug platform and supports the company’s broader strategy across various disease areas.
Brazil Patent Highlights Therapeutic Potential of A3 Adenosine Receptor Agonists
The Brazilian Patent No. BR112015002697-4 protects Can-Fite’s pioneering use of A3 adenosine receptor (A3AR) agonists for sexual dysfunction treatment—a condition linked to vascular, inflammatory, and metabolic processes. Preclinical and clinical evidence from Can-Fite suggests that activating A3AR modulates biological pathways essential for erectile and sexual function. Pnina Fishman, Ph.D., Chairperson and Chief Scientific Officer of Can-Fite BioPharma, remarked that this patent validates the wide-ranging applications of their A3AR technology while expanding the company’s intellectual-property base in a strategically important pharmaceutical region.
This patent aligns with Can-Fite’s ongoing development programs encompassing oncology, inflammatory diseases, and other non-oncologic indications. Additionally, the company is assessing strategic initiatives to maximize the commercial value of its growing patent estate.
Market Response and Strategic Significance
In immediate reaction, Can-Fite’s shares surged nearly 47% during premarket trading on December 26, underscoring strong investor confidence. This market movement reflects optimism regarding the company’s capability to capitalize on this patent to enhance future revenue and secure a competitive position. Securing patent protection in Brazil is strategically vital, given the country’s status as a populous pharmaceutical market with substantial growth potential.
Trump’s Tariffs May Spark an AI Gold Rush
One tiny tech stock could ride this $1.5 trillion wave — before the tariff pause ends.
Moreover, the patent grant arrives amid a wider biotech sector focus on strengthening patent portfolios to protect innovation and reinforce research pipelines. For Can-Fite, this development represents a validation of its scientific approach and a key milestone in consolidating intellectual property necessary for attracting partnerships and investment.
Patent: Market Outlook
The conferment of Patent No. BR112015002697-4 by Brazil’s INPI on December 26, 2025, marks an important step forward for Can-Fite BioPharma. The 47% premarket stock surge illustrates positive investor sentiment about the expanded intellectual-property assets. As the company advances its A3AR agonist programs across multiple therapeutic indications, the strength of this patent portfolio will be instrumental in supporting Can-Fite’s market positioning in Latin America and globally.
